These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11347749)

  • 1. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
    Rave K; Heise T; Pfützner A; Heinemann L; Sawicki PT
    Diabetes Care; 2001 May; 24(5):886-90. PubMed ID: 11347749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy.
    Ruggenenti P; Flores C; Aros C; Ene-Iordache B; Trevisan R; Ottomano C; Remuzzi G
    Diabetes Care; 2003 Feb; 26(2):502-9. PubMed ID: 12547889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
    Plank J; Wutte A; Brunner G; Siebenhofer A; Semlitsch B; Sommer R; Hirschberger S; Pieber TR
    Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
    Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
    Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
    Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
    Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
    Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.
    Hedman CA; Orre-Pettersson AC; Lindström T; Arnqvist HJ
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):107-12. PubMed ID: 11453959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glulisine: a faster onset of action compared with insulin lispro.
    Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
    Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.
    Cengiz E; Tamborlane WV; Martin-Fredericksen M; Dziura J; Weinzimer SA
    Diabetes Care; 2010 May; 33(5):1009-12. PubMed ID: 20150302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.